Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 4/20 | 0.48 |
| ▸ | FPR2 | P25090 | 5/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.46 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.46 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CPB1 | P15086 | 1/20 | 0.45 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4887439 | 1.00 | FOLH1 (0.48) | FOLH1FPR2NPSR1USP30ERAP2 | |
| SCHEMBL4599297 | 0.89 | FPR2 (0.53) | FOLH1FPR2 | |
| SCHEMBL4599293 | 0.89 | FPR2 (0.53) | FOLH1FPR2 | |
| SCHEMBL28216420 | 0.86 | FOLH1 (0.61) | FOLH1FPR2CPB2 | |
| SCHEMBL2724765 | 0.85 | KMT2A (0.57) | FOLH1FPR2NPSR1USP30SMN1; SMN2 | |
| SCHEMBL4735810 | 0.84 | LTA4H (0.53) | CPB1CPB2 | |
| SCHEMBL4882585 | 0.84 | LTA4H (0.53) | CPB1CPB2 | |
| SCHEMBL4735799 | 0.84 | LTA4H (0.53) | CPB1CPB2 | |
| SCHEMBL4736355 | 0.83 | NPSR1 (0.67) | FOLH1FPR2NPSR1SMN1; SMN2MAPK1 | |
| SCHEMBL4736364 | 0.83 | NPSR1 (0.67) | FOLH1FPR2NPSR1SMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-17 | — | — | US | disclosed |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | HAVCR2, ADAR, NSUN2 | FOLH1 771/4885FPR2 3112/4885NPSR1 1083/4885 |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | POLQ, POLI, POLH | FOLH1 1486/4885FPR2 3738/4885NPSR1 4506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.